Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue 3, Pages 224-235
Publisher
Wiley
Online
2015-10-24
DOI
10.1111/dom.12593
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.
- (2015) Sony S. Thazhath et al. DIABETES
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway
- (2015) Na Ao et al. HEPATOLOGY RESEARCH
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance
- (2015) Kim A. Sjøberg et al. JOURNAL OF PHYSIOLOGY-LONDON
- A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
- (2015) Tara Gurung et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function
- (2014) Ling Hinshaw et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production
- (2014) Lucy S. Jun et al. DIABETES
- Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin's Metabolic Action in the Presence of Insulin Resistance
- (2014) W. Chai et al. DIABETES
- Glucagon-Like Peptide 1 Attenuates the Acceleration of Gastric Emptying Induced by Hypoglycemia in Healthy Subjects
- (2014) Mark P. Plummer et al. DIABETES CARE
- Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial
- (2014) Ravi Retnakaran et al. DIABETES CARE
- Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects
- (2014) R. H. A. Becker et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect
- (2014) Nirav Dhanesha et al. Pharmacological Reports
- The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
- (2014) Pia V. Röder et al. PLoS One
- Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
- (2014) Kristina Blaslov WORLD JOURNAL OF GASTROENTEROLOGY
- Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
- (2014) Sarah Anderson et al. Patient Preference and Adherence
- The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp
- (2014) Hui Wu et al. Journal of Diabetes Research
- The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
- (2014) Stephen C. Bain Diabetes Therapy
- GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
- (2013) Kim A. Sjøberg et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
- (2013) Astrid Plamboeck et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
- (2013) M. M. Umapathysivam et al. DIABETES
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- (2013) D. M. Nathan et al. DIABETES CARE
- A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment
- (2013) A. Gastaldelli et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
- (2013) C. Kapitza et al. DIABETES OBESITY & METABOLISM
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
- (2013) Young-Sun Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
- (2012) Michael Camilleri et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Direct effect of GLP-1 infusion on endogenous glucose production in humans
- (2012) M. Seghieri et al. DIABETOLOGIA
- Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
- (2012) Feng Sun et al. Experimental Diabetes Research
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- The migrating motor complex: control mechanisms and its role in health and disease
- (2012) Eveline Deloose et al. Nature Reviews Gastroenterology & Hepatology
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual -Cell Function
- (2011) U. Kielgast et al. DIABETES
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual -Cell Function
- (2011) U. Kielgast et al. DIABETES CARE
- Incretin-Based Therapy and the Quest for Sustained Improvements in -Cell Health
- (2011) D. J. Drucker DIABETES CARE
- Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
- (2011) M. C. Bunck et al. DIABETES CARE
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
- (2011) J. J. Holst et al. DIABETES CARE
- Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
- (2011) Chinmay S. Marathe et al. Experimental Diabetes Research
- Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
- (2011) E. Cersosimo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice
- (2011) Benjamin J. Lamont et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes
- (2010) Kristine J. Hare et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*
- (2010) Adam M. Deane et al. CRITICAL CARE MEDICINE
- Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
- (2010) M. Salehi et al. DIABETES
- Liver Fat Content in Type 2 Diabetes: Relationship With Hepatic Perfusion and Substrate Metabolism
- (2010) L. J. Rijzewijk et al. DIABETES
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
- (2010) Shani Ben-Shlomo et al. JOURNAL OF HEPATOLOGY
- Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion
- (2010) Anne-Barbara Witte et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Age-Dependent Decline in -Cell Proliferation Restricts the Capacity of -Cell Regeneration in Mice
- (2009) S.-I. Tschen et al. DIABETES
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
- (2009) C. Kapitza et al. DIABETIC MEDICINE
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
- Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
- (2009) Adam M. Deane et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- GLP-1 regulates gastroduodenal motility involving cholinergic pathways
- (2009) j. schirra et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
- (2008) Antonio Cervera et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
- (2008) J. de Heer et al. DIABETOLOGIA
- Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion
- (2008) Marzieh Salehi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome
- (2008) p. m. hellström et al. NEUROGASTROENTEROLOGY AND MOTILITY
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
- (2008) Helle Linnebjerg et al. REGULATORY PEPTIDES
- Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state
- (2008) Luis Arnés et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started